Phase II Study of Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer
Upon determination of eligibility, patients will be receive:
- Topotecan
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
overall response rate
Anthony Greco, MD
Principal Investigator
Sarah Cannon Research Institute
United States: Institutional Review Board
SCRI GI 56
NCT00193167
January 2004
April 2006
Name | Location |
---|---|
Tennessee Oncology | Nashville, Tennessee 37203 |